Scholars Central

Conference abstractPublished 10 Aug 2017

Update on biosimilars litigation in the United States

Authors: George C Yu

Schiff Hardin LLP, USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Over seven years have passed since congress enacted the Biologics Price Competition and Innovation Act (BPCIA). Economists estimated that less expensive biosimilar products would result in cost savings amounting to tens billions of dollars. Yet during that period, only a handful of biosimilars have been approved by the US FDA. At least part of the delay in the introduction of biosimilars to the US market stems from uncertainty relating to the litigation provisions of the BPCIA. Many biosimilars developers have objected to provide their confidential application material to the proprietor of the branded biologic prior to the instigation of the litigation. The US Supreme Court in Sandoz v. Amgen (Case No.15-1039 and 15-1195) will decide this issue and also whether the BPCIA requires the biosimilar applicant must always wait 180 days after FDA approval before marketing.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Bioanalysis & Biomedicine
  • BylineArticles whose byline prints “George C Yu”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels